- Home
- NAMM vs ARVN Comparison
NAMM vs ARVN Comparison
Compare NAMM & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMM
- ARVN
- Stock Information
- Founded
- NAMM 2024
- ARVN 2015
- Country
- NAMM Cayman Islands
- ARVN United States
- Employees
- NAMM N/A
- ARVN N/A
- Industry
- NAMM
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- NAMM
- ARVN Health Care
- Exchange
- NAMM Nasdaq
- ARVN Nasdaq
- Market Cap
- NAMM 410.8M
- ARVN 456.2M
- IPO Year
- NAMM N/A
- ARVN 2018
- Fundamental
- Price
- NAMM $2.77
- ARVN $7.32
- Analyst Decision
- NAMM
- ARVN Buy
- Analyst Count
- NAMM 0
- ARVN 22
- Target Price
- NAMM N/A
- ARVN $20.21
- AVG Volume (30 Days)
- NAMM 1.3M
- ARVN 2.0M
- Earning Date
- NAMM 01-01-0001
- ARVN 08-06-2025
- Dividend Yield
- NAMM N/A
- ARVN N/A
- EPS Growth
- NAMM N/A
- ARVN N/A
- EPS
- NAMM N/A
- ARVN N/A
- Revenue
- NAMM N/A
- ARVN $372,800,000.00
- Revenue This Year
- NAMM N/A
- ARVN $7.57
- Revenue Next Year
- NAMM N/A
- ARVN N/A
- P/E Ratio
- NAMM N/A
- ARVN N/A
- Revenue Growth
- NAMM N/A
- ARVN 299.57
- 52 Week Low
- NAMM $2.56
- ARVN $5.90
- 52 Week High
- NAMM $55.00
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- NAMM N/A
- ARVN 52.39
- Support Level
- NAMM N/A
- ARVN $6.96
- Resistance Level
- NAMM N/A
- ARVN $7.30
- Average True Range (ATR)
- NAMM 0.00
- ARVN 0.39
- MACD
- NAMM 0.00
- ARVN 0.06
- Stochastic Oscillator
- NAMM 0.00
- ARVN 71.19
About NAMM Namib Minerals Ordinary Shares
Namib Minerals is a gold producer, developer and explorer with operations focused in Zimbabwe.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.